Combined photodynamic therapy and intravitreal bevacizumab for idiopathic polypoidal choroidal vasculopathy: one-year follow-up by Romano, Mario R et al.
© 2010 Romano et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2010:4 1237–1241
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1237
CAse seRies
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OPTH.S12577
Combined photodynamic therapy and intravitreal 
bevacizumab for idiopathic polypoidal choroidal 
vasculopathy: one-year follow-up
Mario R Romano1
Ugo Cipollone2
Francesco semeraro3
Michele Rinaldi4
Ciro Costagliola1
1Dipartimento di scienze per la  
salute, Università degli studi del 
Molise, Campobasso; 2Dipartimento  
di Oftalmologia, Ospedale G  
Vietri, Larino, Campobasso; 3Clinica 
Oculistica, Università degli studi di 
Brescia, Brescia; 4Clinica Oculistica, 
ii Università degli studi di Napoli, 
Napoli, italy
Correspondence: Mario R Romano 
Dipartimento di scienze per la salute, Via 
F de sanctis, 86100 Campobasso, italy 
Tel +44 079 6019 2539 
Fax +44 015 1706 5905 
email romanomario@email.it
Objective: To report the efficacy and safety of combined photodynamic therapy (PDT) and 
intravitreal bevacizumab (IVB) injection in the treatment of idiopathic polypoidal choroidal 
vasculopathy (IPCV).
Material and methods: A prospective case series of 10 eyes of 10 consecutive patients affected 
by IPCV with subfoveal involvement. PDT plus IVB (1.25 mg/0.05 mL) injection two weeks later 
was performed in all patients. Two adjunctive injections of bevacizumab were scheduled at four 
and eight weeks after the initial treatment. Best-corrected visual acuity (BCVA),   fluorescein and 
indocyanine green angiographies, and optical coherence tomography were obtained at baseline, 
and at one, three, six, nine, and 12 months.
Results: The combined treatment led to an improvement of both neurosensory detachment and 
pigmented epithelial detachment in all eyes, with a decrease of exudation and regression of 
macular thickness, which remained stable to the end of follow-up. However, BCVA remained 
stable over the 12 months of follow-up.
Conclusion: These findings demonstrate that PDT/IVB combined therapy is able to achieve 
morphologic stabilization of the IPCV lesion, through a rapid decrease of macular thickness 
and regression of the size of polypoidal vascular lesion.
Keywords: combined treatment, idiopathic polypoidal choroidal vasculopathy, age-related 
macular degeneration, intravitreal bevacizumab, photodynamic therapy
Introduction
The term “idiopathic polypoidal choroidal vasculopathy” (IPCV) was coined by 
  Yannuzzi et al to describe a disease of the choroidal circulation characterized by branch-
ing choroidal vessels with polyp-like terminal aneurysmal dilations, and recognized as 
a clinical entity separate from age-related macular degeneration.1 The vascular abnor-
malities are frequently located in the peripapillary area or within the macula, where 
they may be responsible for serious visual loss. Large serous-hemorrhagic pigmented 
epithelial detachments (PEDs) are another clinical characteristic of the disease.3 IPCV 
is not a rare condition among patients presumptively diagnosed with exudative age-
related macular degeneration (7.9% of 167 patients in a mixed population).2 Both sexes 
are equally affected, but a predilection for more darkly pigmented patients has been 
observed, although white patients still represent the majority of polypoidal choroidal 
vasculopathy patients in clinical practice.1,2
Treatment for IPCV is not yet well established. A conservative approach is recom-
mended, unless the lesion is associated with persistent or progressive exudative change, 
threatening central vision.4 In this case, conventional thermal laser treatment of the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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leaking polypoidal choroidal vascular abnormality may be 
successful in causing resolution of the serous-hemorrhagic 
manifestations. In the more compromised varieties, photo-
dynamic therapy (PDT) with verteporfin has demonstrated 
promising results,5,6 although definitive outcomes to confirm 
these anecdotal observations are not yet available. We herein 
report the clinical course of 10 consecutive patients affected 
by IPVC in whom the efficacy and safety of PDT plus intra-
vitreal bevacizumab (IVB) injection has been analyzed.
Materials and methods
Our series consisted of 10 eyes of 10 consecutive patients 
(aged 68.7 ± 13 years, male to female ratio 7:3) diagnosed 
with IPCV and subfoveal involvement, who were refractory 
to previous treatment with photodynamic therapy alone. 
Demographic characteristics for the patients are summarized 
in Table 1. The diagnosis of IPCV was based on clinical 
examination and on multiple areas of PED seen on indocya-
nine green angiograms (ICGA) as a network of branching 
vessels and polypoidal lesions in the macular area located at 
the margin of the PEDs. All patients underwent a complete 
ophthalmic examination including fluorescein angiography, 
ICGA, and optical coherence tomography (OCT) at baseline 
and at one, three, six, nine, and 12 months of follow-up. Best-
corrected visual acuity (BCVA) was measured with Early 
Treatment Diabetic Retinopathy Study (ETDRS) charts.
PDT followed by IVB (1.25 mg/0.05 mL) injection two 
weeks later were performed in all cases. Two adjunctive 
injections of bevacizumab were scheduled at four and eight 
weeks after the initial treatment. The patients were given 
detailed information about the natural course of the disease 
and about the results of alternative therapeutic and surgical 
approaches for IPCV before being offered IVB. Written 
informed consent was obtained from all subjects after a 
description of the procedure to be used. The local human 
subjects review committees (Brescia, Campobasso, Larino, 
Napoli) approved the project.
Results
Five patients were phakic and five were pseudophakic. Base-
line BCVA ranged from 20/400 to 20/100. BCVA, macular 
thickness, and angiographic variations during the 12 months 
of follow-up are detailed in Table 2. A neurosensory retinal 
detachment and at least one PED were observed at baseline 
in all recruited patients.
After the third IVB injection, angiography showed a 
regression in size of the polypoidal vascular lesions and a 
reduction in leakage. OCT scans documented an improvement 
in neurosensory retinal detachment and a reduction of PED 
(Figures 1 and 2). In five cases (patients 2, 5, 6, 8, and 10), 
both retinal and choroidal angiograms did no longer show 
signs of vascular activity. In four cases (patients 1, 4, 7, and 
9), the PED was no longer visible at slit-lamp examination or 
fluorescein angiography, and the choroidal neovascularization 
also seemed to have decreased, with involution of the chor-
oidal polyp-like structure, together with a minimal residual 
leakage (area of leakage occupying ,50% of the area noted 
at baseline). In one case (patient 3), no signs of regression, 
in terms of reduction in leakage or size of the lesion, could 
be seen at 12-month follow-up after combined therapy.
Regression of macular thickness, assessed by OCT 
examination, occurred in all the patients and remained stable 
over the entire follow-up period. In fact, after one month of 
PDT, the mean reduction in macular thickness was about 
30%. At the end of the 12-month follow-up, a modest   further 
increase of about 40% was documented (Table 2). The treat-
ment was not able to ameliorate VA significantly, which 
remained unwaivering at each assessment. No side effects 
were reported due to the combined treatment.
Discussion
Polypoidal choroidal vasculopathy seems to be a distinct 
clinical entity that should be differentiated from other types 
of occult choroidal neovascularization associated with age-
related macular degeneration and other known choroidal 
degenerative, inflammatory, and ischemic disorders. The 
principal abnormality seen in IPCV , notably the branching 
vascular network and polypoidal structures at the borders of 
the lesion, seem to be unique to the disorder.
In this prospective interventional case series, the com-
bination of PDT and IVB has been able to treat the lesion 
in patients affected by IPCV . A potential benefit in terms of 
stabilization of leakage and lesion size was documented, but it 
Table 1 Baseline patient characteristics undergoing intravitreal 
bevacizumab  treatment  for  a  polypoidal  choroidal  vascular 
lesion
Patient Gender Age Eye Lens status Visual acuity
1 M 54 Right Phakic 20/120
2 M 63 Left Phakic 20/100
3 F 77 Right Pseudophakic 20/120
4 M 88 Right Pseudophakic 20/400
5 M 80 Left Pseudophakic 20/200
6 M 78 Right Pseudophakic 20/400
7 F 57 Right Phakic 20/400
8 M 53 Left Phakic 20/200
9 F 65 Right Phakic 20/120
10 M 71 Right Pseudophakic 20/200Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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was not associated with significant recovery of visual acuity. 
The PDT-IVB combination led to a rapid decrease in macular 
thickness, with a significant regression in terms of retinal 
edema and subretinal fluid, being successful in stabilizing 
the lesion. IPCV has been reported in 85% of patients with 
PED, subretinal hemorrhages, and exudation in the macular 
area on ICGA in patients with hemorrhagic AMD.3 The most 
frequent clinical complication after treatment could be the 
exudative retinal detachments, retinal pigment epithelium 
tears, and massive bleeding.
In patients with serous-sanguineous detachment of the 
pigment epithelium, particularly those with increased risk 
factors, such as African-American or Asian race, ICGA 
should be performed to evaluate the choroidal vascular 
abnormality in an attempt to establish a more definitive 
  diagnosis. If the characteristic vascular lesion of IPCV is 
seen, a conservative approach should be entertained unless 
there is a persistent or progressive exudative change that 
is threatening the central macula. In that event, there may 
be a rationale for photocoagulation treatment of leaking 
aneurysmal or polypoidal components within the vascular 
lesion, but not the entire vascular complex.4
Several experimental treatments, such as focal laser 
photocoagulation, thermal laser, and PDT have demonstrated 
only a potential success rate with several complications. 
Laser photocoagulation and thermal laser are advised for 
the treatment of IPCV if the lesion does not involve the 
fovea. This treatment is actually considered a palliative 
treatment for IPCV, and the final vision achieved is poor 
and relapse is frequent.4,5 PDT with verteporfin for IPCV 
involving the fovea appears to be a viable option, but the 
treatment could be complicated by iatrogenic bullous exu-
dative retinal detachments that resemble rhegmatogenous 
detachments6 or by the risk of massive bleeding. Moreover, 
as demonstrated in the Verteporfin in Photodynamic Therapy 
study, the visual   outcome of PDT for occult choroidal 
  neovascularization in age-related macular degeneration 
was generally   compromised, because more than 50% of 
Table 2 Best-corrected visual acuity and macular thickness variation during 12 months of follow-up after intravitreal bevacizumab 
treatment for a polypoidal choroidal vascular lesion
Patient 
number
Visual acuity Macular thickness Last 
FA
Baseline 1 3 6 9 12 Baseline 1 3 6 9 12
1 20/120 20/80 20/80 20/80 20/100 20/100 380 210 220 210 210 210 Min
2 20/100 20/100 20/100 20/100 20/100 20/100 410 240 230 230 220 220 No leakage
3 20/120 20/80 20/100 20/100 20/120 20/120 460 320 300 285 280 280 Prev*
4 20/400 20/100 20/200 20/100 20/120 20/100 370 320 320 290 260 260 Min+
5 20/200 20/100 20/80 20/80 20/80 20/80 380 290 210 210 220 220 No leakage
6 20/400 20/200 20/200 20/100 20/80 20/80 320 240 220 220 215 215 No leakage
7 20/400 20/100 20/100 20/80 20/100 20/80 340 260 230 230 230 230 Min
8 20/200 20/80 20/60 20/80 20/80 20/80 350 210 230 230 220 220 No leakage
9 20/120 20/120 20/100 20/80 20/80 20/80 440 300 260 240 210 210 Min
10 20/200 20/200 20/200 20/120 20/120 20/100 390 270 260 260 290 280 No leakage
Note: *Prev = area of leakage occupying .50% of the area noted at baseline; + Min = area of leakage occupying ,50% of the area noted at baseline.
Abbreviation: FA, fluorescein angiography.
Figure 1 A fluorescein, B indocyanine green, early phase, C indocyanine green, 
later phase baseline angiographic characteristics. The angiograms showed choroidal 
polyp-like structure together with subfoveal leakage. D fluorescein angiography, 
E indocyanine green, early phase, F indocyanine green, later phase at 12-months 
follow-up. The angiograms showed a regression in size of the polypoidal vascular 
lesions and a reduction in leakage.
Figure 2 At 12-month follow-up, the opical coherence tomography scans showed 
an improvement of neurosensory retinal detachment and a reduction of pigment 
endothelial detachment B from baseline A.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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verteporfin-treated eyes developed visual loss of three or 
more lines after one year.7
Bevacizumab is a mouse-derived monoclonal antibody 
designed to neutralize the effects of all isoforms of vascular 
endothelial growth factor (VEGF). It plays a role as a chor-
oidal survival factor for the choriocapillaris, maintaining the 
permeability and fenestration of the vessels. This antigen-
binding monoclonal antibody has never been tested before 
for the treatment of occult choroidal neovascularization 
characterized by polyp-like vessels.
One of the reasons for the less favorable outcome in 
treating an occult lesion such as IPCV might be the col-
lateral damage to adjacent structures, such as choriocapil-
laris hypoperfusion and retinal pigment epithelium atrophy, 
due to the effect of PDT.8 The associated damage results 
in retinal edema and release of angiogenic factors, with 
reduction of retinal function demonstrated by multifocal 
electroretinography.9
Therefore, after an unsuccessful single treatment with 
PDT alone, we thought that adding anti-VEGF treatment 
might increase the efficacy of PDT in the treatment of this 
particular kind of choroidal neovascularization. Because the 
antiangiogenic effects of PDT with verteporfin are usually 
transient, a combination of PDT with an intermediate-acting 
antiangiogenic agent like IVB may be a promising treatment 
option by creating a longer lasting and possibly synergistic 
effect on choroidal neovascularization.
The first case report described the clinical course of a patient 
treated with IVB, who had received prior treatments with PDT 
and intravitreal pegaptanib with a poor therapeutic response.10 
Within four weeks of follow-up after a single IVB, an improve-
ment of VA for hand motion to 20/400 coincident with resolution 
of subretinal fluid was achieved. Moreover, the macula remained 
without exudation for 12 months post treatment.
The first reported series consisted of 11 IPCV patients 
treated with IVB and a three-month follow-up.11 An addi-
tional injection was administered in five of 11 eyes. The main 
outcomes were changes in the polypoidal vessels, foveal 
height, and BCVA, evaluated before and three months after 
treatment. At month 3, a resolution of polyps had occurred in 
one eye, whereas residual or enlarged lesions were recorded 
in the other 10 eyes. The foveal height decreased significantly 
one month after IVB, but at three months no significant 
decrease was observed, although an additional injection had 
been performed. The BCVA did not improve significantly. 
The conclusion of the study was that IVB may reduce the 
fluid from choroidal vasculopathy but seems to be ineffective 
for diminishing its choroidal vascular changes.
Sato et al described 12-month follow-up results for 29 
treatment-naïve IPCV patients who received combined ther-
apy (IVB-PDT-verteporfin). The mean number of treatments 
with combined therapy averaged 1.59. Polypoidal lesions 
recurred in six eyes (21%). The authors concluded that the 
combined treatment seemed to be effective for improving 
visual acuity and reducing retreatment rates and complica-
tions.12 In contrast, Lim et al showed 12-month results for 
10 eyes affected by IPCV and randomized to either IVB or 
combined treatment. IVB alone had similar efficacy and 
safety to IVB plus PDT for treatment of patients, including 
those who were treatment-naïve.13
In our study, the combined treatment led to morphologic 
stabilization of IPCV lesions, seen as a rapid decrease in 
macular thickness together with a regression of the size of 
polypoidal vascular lesions, but this was not accompanied 
by an increase in BCVA.
There are several important limitations to this study, 
including lack of a control group, a small number of patients, 
and inadequate low functional changes measurement. The 
encouraging results obtained in these patients emphasize 
the need for further randomized clinical studies of combined 
treatment for IPCV lesions.
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